iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma
Background: Benign thyroid goiter (BTG) and papillary thyroid carcinoma (PTC) are often interchangeably misdiagnosed. Methods: Pooled urine samples of patients with BTG (n = 10), patients with PTC (n = 9) and healthy controls (n = 10) were subjected to iTRAQ analysis and immunoblotting. Results: The...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Published: |
Elsevier
2018
|
| Subjects: |
| _version_ | 1825721743305605120 |
|---|---|
| author | Jayapalan, Jaime Jacqueline Lee, Cheng Siang Lee, Ching Chin Ng, Khoon Leong Junit, Sarni Mat Hashim, Onn Haji |
| author_facet | Jayapalan, Jaime Jacqueline Lee, Cheng Siang Lee, Ching Chin Ng, Khoon Leong Junit, Sarni Mat Hashim, Onn Haji |
| author_sort | Jayapalan, Jaime Jacqueline |
| collection | UM |
| description | Background: Benign thyroid goiter (BTG) and papillary thyroid carcinoma (PTC) are often interchangeably misdiagnosed. Methods: Pooled urine samples of patients with BTG (n = 10), patients with PTC (n = 9) and healthy controls (n = 10) were subjected to iTRAQ analysis and immunoblotting. Results: The ITRAQ analysis of the urine samples detected 646 proteins, 18 of which showed significant altered levels (p < 0.01; fold-change > 1.5) between patients and controls. Whilst four urinary proteins were commonly altered in both BTG and PTC patients, 14 were unique to either BTG or PTC. Amongst these, four proteins were further chosen for validation using immunoblotting, and the enhanced levels of osteopontin in BTG patients and increased levels of a truncated gelsolin fragment in PTC patients, relative to controls, appeared to corroborate the findings of the iTRAQ analysis. Conclusion: The data of the present study is suggestive of the potential application of urinary osteopontin and gelsolin to discriminate patients with BTG from those with PTC non-invasively. However, this needs to be further validated in studies of individual urine samples. |
| first_indexed | 2024-03-06T05:55:00Z |
| format | Article |
| id | um.eprints-21742 |
| institution | Universiti Malaya |
| last_indexed | 2024-03-06T05:55:00Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | um.eprints-217422019-08-02T02:00:09Z http://eprints.um.edu.my/21742/ iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma Jayapalan, Jaime Jacqueline Lee, Cheng Siang Lee, Ching Chin Ng, Khoon Leong Junit, Sarni Mat Hashim, Onn Haji R Medicine Background: Benign thyroid goiter (BTG) and papillary thyroid carcinoma (PTC) are often interchangeably misdiagnosed. Methods: Pooled urine samples of patients with BTG (n = 10), patients with PTC (n = 9) and healthy controls (n = 10) were subjected to iTRAQ analysis and immunoblotting. Results: The ITRAQ analysis of the urine samples detected 646 proteins, 18 of which showed significant altered levels (p < 0.01; fold-change > 1.5) between patients and controls. Whilst four urinary proteins were commonly altered in both BTG and PTC patients, 14 were unique to either BTG or PTC. Amongst these, four proteins were further chosen for validation using immunoblotting, and the enhanced levels of osteopontin in BTG patients and increased levels of a truncated gelsolin fragment in PTC patients, relative to controls, appeared to corroborate the findings of the iTRAQ analysis. Conclusion: The data of the present study is suggestive of the potential application of urinary osteopontin and gelsolin to discriminate patients with BTG from those with PTC non-invasively. However, this needs to be further validated in studies of individual urine samples. Elsevier 2018 Article PeerReviewed Jayapalan, Jaime Jacqueline and Lee, Cheng Siang and Lee, Ching Chin and Ng, Khoon Leong and Junit, Sarni Mat and Hashim, Onn Haji (2018) iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma. Clinical Biochemistry, 53. pp. 127-131. ISSN 0009-9120, DOI https://doi.org/10.1016/j.clinbiochem.2018.01.008 <https://doi.org/10.1016/j.clinbiochem.2018.01.008>. https://doi.org/10.1016/j.clinbiochem.2018.01.008 doi:10.1016/j.clinbiochem.2018.01.008 |
| spellingShingle | R Medicine Jayapalan, Jaime Jacqueline Lee, Cheng Siang Lee, Ching Chin Ng, Khoon Leong Junit, Sarni Mat Hashim, Onn Haji iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma |
| title | iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma |
| title_full | iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma |
| title_fullStr | iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma |
| title_full_unstemmed | iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma |
| title_short | iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma |
| title_sort | itraq analysis of urinary proteins potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma |
| topic | R Medicine |
| work_keys_str_mv | AT jayapalanjaimejacqueline itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma AT leechengsiang itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma AT leechingchin itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma AT ngkhoonleong itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma AT junitsarnimat itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma AT hashimonnhaji itraqanalysisofurinaryproteinspotentialuseofgelsolinandosteopontintodistinguishbenignthyroidgoiterfrompapillarythyroidcarcinoma |